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Abstract  In this work, a novel and simple bone mor-
phogenetic protein (BMP)-2 carrier is developed, 
which enables localized and controlled release of 
BMP-2 and facilitates bone regeneration. BMP-2 is 
localized in the gelatin methacrylate (GelMA) micro-
patterns on hydrophilic semi-permeable membrane 
(SNM), and its controlled release is regulated by the 
concentration of GelMA hydrogel and BMP-2. The 
controlled release of BMP-2 is verified using com-
putational analysis and quantified using fluorescein 
isothiocyanate-bovine serum albumin (FITC-BSA) 
diffusion model. The osteogenic differentiation of os-
teosarcoma MG-63 cells is manipulated by localized 
and controlled BMP-2 release. The calcium deposits 
are significantly higher and the actin skeletal networks 
are denser in MG-63 cells cultured in the BMP-2- 
immobilized GelMA micropattern than in the ab-
sence of BMP-2. The proposed BMP-2 carrier is ex-
pected to not only act as a barrier membrane that can 
prevent invasion of connective tissue during bone 
regeneration, but also as a carrier capable of localiz-
ing and controlling the release of BMP-2 due to 
GelMA micropatterning on SNM. This approach can 
be extensively applied to tissue engineering, includ-
ing the localization and encapsulation of cells or 
drugs.  
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Introduction 
Bone regeneration is the coordinated response of the 
body to injured or damaged bones1-3. This is physio-
logically complicated and involves unknown signal-
ing pathways and processes, which are regulated by 
different cells, cytokines, and growth factors4-6. Au-
tologous bone grafting is still the gold standard for 
bone regeneration treatment7-9. Despite the obvious 
advantages of immune compatibility and excellent 
osteoconductive, osteoinductive, and osteogenic pro-
perties, the application of bone autografting is limited 
by the dearth of donor tissue supply and risk of donor 
site complications. Similarly, the use of allografts and 
xenografts has been constrained by more serious pro-
blems such as immune responses or infections10,11. 
Although these treatments have significantly contrib-
uted to bone regeneration, they require complicated, 
appropriate, and reliable manipulations for successful 
bone regeneration12. To address these problems, com-
prehensive biomaterial-based substitutes are being 
used for bone regeneration with autograft, allograft, 
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and xenograft procedures13-16. Recently, groundbrea-
king research in bone regenerative medicine has 
suggested the use of a combination of biomateri-
al-based bone substitutes and cells17. These attempts 
have revealed new possibilities for circumventing the 
shortcomings of only cell-based therapies. The major 
limitations of the current bone substitutes include lack 
of properties that support complex cell-microenviron-
ment interactions, difficulty in generating bone tissue 
remodeling due to cell necrosis, and loss of function 
within the damaged bone tissue18. Therefore, regula-
tion of osteogenic differentiation is one of the crucial 
challenges in bone regenerative medicine for suc-
cessful bone regeneration therapy. One emerging ap-
proach involves the use of bone morphogenetic pro-
teins (BMPs), which are members of the transform-
ing growth factor-beta (TGF-β) superfamily of pro-
teins. BMPs play a pivotal role in the regulation of 
bone induction and repair as growth factors, cyto-
kines, and metabologens19-21. In addition, BMPs play 
an important role in cell-cell interactions, such as au-
tocrine or paracrine interactions, by associating with 
cell surface BMP receptors as homo or heterodimers, 
which affect various cell types. BMPs are stored in 
the bone matrix and are used by osteogenic cells for 
bone reconstruction or remodeling22. In terms of 
BMP pharmacokinetics, the microenvironmental con-
ditions, BMP release rate, concentration, and delivery 
method, and carrier materials and surface conditions 
are known to be critical elements affecting bone re-
generation. However, a quantitative delivery or tran-
sport system for BMPs is required for effectively us-
ing BMPs for enhancement of bone regeneration. 
Among the BMPs, BMP-2 has been established as 
the osteogenic BMP based on its dominant bone-in-
ducing activity. The conventional BMP-2 delivery 
systems involve combinations of biocompatible ma-
terials as carriers (i.e., collagen, hyaluronic acid, poly 
(ethylene glycol) diacrylate, and gelatin)23,24. Alt-
hough collagen has been approved as the carrier for 
BMP-2 by the Food and Drug Administration (FDA) 
of USA, it is known that BMP-2 has low binding af-
finity for collagen12,25. Furthermore, collagen-enca-
psulated BMP-2 shows uncontrolled and unpredicta-
ble release, which can cause side effects at ectopic 
sites. To address these issues, various approaches have 
been developed, which include methods for BMP-2 
loading, carriers that maintain BMP-2 in a stable state, 
and biomaterials that ensure controlled and predicta-
bly localized release of BMP-226-29. To use BMP-2 in 
a delivery system, the physiochemical problems, as 
well as the biological barriers due to the poor affinity 
of BMP-2 with carriers, and the difficulty in control-
ling the BMP release kinetics have to be suitably re-
solved. Currently, biocompatible polymers such as 
polylactic acid (PLA), chitosan, gelatin, sodium al-
ginate, poly(ε-caprolactone) (PCL), and poly(lactide- 
co-glycolide) (PLGA) are being used for creating a 
BMP-2 delivery system, and engineering technolo-
gies (micro-/nanotechnology) are being investigated 
as tools that can provide precise and targeted delivery 
and/or controlled release of a drug or therapeutic sub-
stance. Lately, the micropatterned gelatin array work-
ed as the 3D platform for guiding the formation of 
physiological morphologies of osteocytes and odon-
toblasts30. Also, the microstructural pattern promoted 
osteoblast cells growth, proliferation, osteogenic dif-
ferentiation, mineralization, and bone formation31. 
These approaches should include methods for target-
ed and reliable drug delivery, controlled drug release, 
dose titration, and even drug monitoring32. The emer-
ging micro- and nanotechnology-based approaches 
enable control over delivery owing to the ability to 
manipulate the size and the shape of the carrier in 
simple, cost-effective, and reliable manner. The pur-
pose of the present study is to develop a novel BMP 
-2 carrier system for localized and controlled release 
of BMP-2 using GelMA hydrogel micropatterns on a 
SNM33,34. The immobilization of BMP-2 on the SNM 
within the GelMA hydrogel micropatterns may ena-
ble its use as a BMP-2 carrier and barrier-membrane 
for bone regeneration in the clinic. The developed 
SNM and GelMA hydrogel-based BMP-2 carrier 
system can be used to regulate the precise delivery of 
various bone regenerative medicines.  
 
Results and Discussion  
Hydrophilic PU-PF SNM 
The entire process of GelMA hydrogel micropattern-
ing on SNM is shown in Figure 1. In the preliminary 
test with hydrophobic polyurethane (PU)-based SNM 
as the substrate, the GelMA solution was partially 
cross-linked and did not attach onto the SNM (Figure 
S1, Supporting Information). This indicated that for 
the GelMA hydrogel to cross-link and adhere onto 
the SNM, the GelMA solution has to be sufficiently 
absorbed between the SNM prior to crosslinking. 
However, the GelMA solution did not completely 
penetrate the interstitial space of the SNM because of 
its strong hydrophobicity in pure PU SNM. Hence, 
we attempted to improve the wettability of pure PU 
SNM using polyethylene oxide (PEO)-based Pluronic  
 




Figure 1. Formation of GelMA hydrogel micropatterns on the semi-permeable nanoporous membrane; (a)−(c) filling of GelMA 
solution into the PDMS concave micromold, (d)−(e) UV light exposure of the GelMA solution for crosslinking with the mold 
through the covered membrane, and (f)−(g) GelMA hydrogel micropatterns on the membrane after separation of the mold. 
 
 
Figure 2. (a) SEM image of electrospun PU-PF SNM, (b) covered PU-PF SNM onto PDMS concave mold, (c) fabricated PDMS 
concave micromold, and (d) cross-section view of PDMS concave mold. 
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F-127 (PF) blending. The novel hydrophilic PU-PF 
SNM with a uniform nanofiber diameter was suc-
cessfully produced without droplets, as observed us-
ing scanning electron microscopy (Figure 2a). The 
diameter of the randomly oriented average nanofiber 
ranged from 200 nm to 500 nm, and inter-fiber pores 
were uniformly generated throughout the PU-PF SNM. 
In terms of altered surface wettability, the contact an-
gle recorded on the PU SNM surface was 82.89 ± 
1.3 °; however, in PU-PF SNM, the liquid droplets 
spread completely on the surface, corresponding to a 
contact angle of 0 ° (Figure S2) due to extension of 
PEO chains, as reported previously35. The attenuated 
total reflection Fourier-transform infrared (ATR- 
FTIR) spectroscopy analysis revealed quantitative 
information regarding the blended PF. A C-O bond 
appeared at 1103-1 in the hydrophilic PU-PF SNM, 
which increased due to the presence of PF. These re-
sults show that semipermeable physical properties 
with high porosity are sufficient for transmitting ul-
tra-violet (UV) for crosslinking of GelMA hydrogels 
(Figure S3a,b, Supporting Information). The synthe-
sized GelMA hydrogel was confirmed using an ATR- 
FTIR spectra (Figure S3c, Supporting Information). 
The identified methacrylation spectra of gelatin were 
similar to that reported previously36, except for a 
broad peak for the hydroxyl group at 3,500 cm-1 and 
subdued peaks at 1,000 ~ 1,700 cm-1 for the GelMA 
hydrogel, which can be attributed to the –OH group, 
indicating that both peaks originated from the C=C 
bonds37. 
 
Micropatterning for GelMA Hydrogel 
Based on the polydimethylsiloxane (PDMS) concave 
mold, the single pattern size of the GelMA hydrogel 
was 250 μm, although the actual average size was 
approximately 270 μm on the image due to the 
swelling of the GelMA hydrogel. As shown in Figure 
3a, the GelMA hydrogel showed successfully hemi-
spheric cross-linking on flat smooth cover glass sur-
face, as well as on porous mesh-like PU-PF SNM. In 
Figure 3b,c, the addition of fluorescent labeled 
FITC-BSA and trypan blue confirmed that the mi-
cropatterns were clearly formed only in the targeted 
region, indicating that crosslinking and patterning 
were possible even if suitable materials were added 
to the GelMA hydrogel. Figure 3d,e shows the Z- 
stack image observed using a confocal laser micro-
scope. When the fixed micro-beads were monitored 
while moving along the Z-axis, we observed that the 
fluorescent beads were evenly dispersed in the pat-
tern. These results involve that even if BMP-2 is 
immobilized and patterned in the GelMA hydrogel, it 
can be immobilized stably and homogeneously 
therein. The GelMA hydrogel was intact even after 
pressing it with the tip of an ink pen (Figure 4). The 
compressive strength was determined from both the 
crosslinking density of the GelMA hydrogel and the 
adhesion between the GelMA hydrogel and SNM. 
The compressive strengths were 1.064 MPa at the 
lowest concentration (2.5% w/v), 4.556 MPa at the 
middle concentration (5% w/v), and 6.504 MPa at the 
highest concentration (10% w/v). If the compressive 
strength is weak, the surrounding environment and 
hydrostatic pressure may crack the GelMA hydrogel 
pattern. On the contrary, if the strength is too high, 
the slow release of BMP-2 can be suppressed due to 
the high density of GelMA; however, the value mea-
sured in this experiment has been analyzed previous-
ly and found to be suitable for controlled BMP-2 re-
lease without affecting the GelMA pattern as a visco-
elastic material38-40. Even when the same specimen 
was pulled horizontally lengthwise and diagonally, 
the patterned GelMA hydrogel remained reliably at-
tached and did not separate from the SNM. These re-
sults showed that GelMA hydrogels are strongly at-
tached, cross-linked, and patterned on the surface of 
the three-dimensional network-based SNM using the 
novel method proposed in the study. 
 
Cross-linking for the BMP-2 Encapsulated  
GelMA Micropatterning on SNM 
As predicted, the hemisphere radius tended to de-
crease with increase in the concentration of the 
GelMA hydrogel and BMP-2, and accurate patterning 
was formed as the hydrophilicity of SNM increased. 
Although the increase in UV irradiation intensity and 
exposure time was increased at high concentration of 
the GelMA hydrogel, the pattern completeness could 
not be improved significantly. When hydrophobic 
SNM was used, it remained in the PDMS mold with-
out adhesion to SNM at all GelMA hydrogel concen-
trations (Figure S1, Supporting Information). How-
ever, the adhesion pattern was partially observed in 
the hydrophilic SNM, although the concentration of 
the GelMA hydrogel was increased. To confirm the 
possibility of loading of BMP-2 in the GelMA hy-
drogel, fluorescent beads and FITC-BSA were used 
instead of BMP-2 (which is transparent and difficult 
to observe), and pattern formation was observed with 
increasing GelMA hydrogel concentration. At the 
lowest concentration, the FITC-BSA distribution was 




Figure 3. Micropatterned GelMA hydrogel. (a) Optical image of SNM, (b) FITC-BSA mixed fluorescence image on cover-glass, 
(c) Trypan-blue mixed GelMA micropattern on SNM, (d) fluorescent micro-particles immobilized on GelMA micropattern on cov-
er-glass, (e) confocal microscopy Z-stack of rhodamine B mixed micropatterned GelMA hydrogel, and (f) image of gallery view of 
rhodamine B mixed micropatterned GelMA hydrogel on cover-glass. 
 
 
Figure 4. Compressive strength and adhesion tests. (a−b) Compressed GelMA hydrogel micropatterns on SNM, (c−d) horizontal 
and vertical stretching test, and (e−f) diagonally stretched SNM containing GelMA hydrogel micropatterns. 
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Table 1. Relationship between the GelMA hydrogel, BMP-2, and SNM. 
 
Concentration of GelMA Hydrogel 
 

























































uniform throughout the pattern; however, at the high-
est concentration of the GelMA hydrogel, FITC-BSA 
was observed locally, as shown in Figure S4 (Sup-
porting Information). GelMA patterning containing 
BMP-2 on the surface of SNM requires hydrophilic 
rather than hydrophobic SNM, and it helps to pene-
trate the GelMA hydrogel rapidly and easily between 
SNM interlayers due to high surface tension. In addi-
tion, SNM as a substrate must possess sufficient tran-
smittance to allow UV light to cross the GelMA in 
the PDMS mold through the SNM. As summarized in 
Table 1, change in BMP-2 concentration affected the 
pattern completeness of the GelMA hydrogel. Thus, 
the lowest concentration (2.5% w/v) of the GelMA 
hydrogel was used as the optimal condition for the 
best micropattern with 2000 ng/mL BMP-2. 
 
Analysis of Localized and Controlled Release 
Figure 5 shows the computationally simulated time- 
dependent drug concentration distribution, which de-
pended on the drug diffusion coefficients in the 
GelMA hydrogel models, for 3 days (i.e. 4,320 min). 
This simulation analyzes how the diffusion-driven re-
lease of BMP-2 might occur from the micropatterned 
GelMA hydrogel models of different concentrations. 
As expected, BMP-2 diffuses from the GelMA hy-
drogel into the surrounding, including the culture 
medium, over time, and concentration distribution is 
affected by the diffusion coefficients. We simulated 
three different diffusion coefficient models and in-
vestigated the spatiotemporal variations of BMP-2 
for the entire domain, including the GelMA hydrogel 
structure and the surrounding after every 60 min. At 
60 min, BMP-2 molecules diffused slightly through 
the interface between the GelMA hydrogel and the 
surrounding, although the diffusion rates for each 
case appeared to differ slightly. At 1,440 min (1 day), 
the highest density model retained more BMP-2 (ap-
proximately 0.6 mol/m3) at the center of the patterned 
GelMA hydrogel, whereas other lower density mod-
els retained approximately 0.5 mol/m3 and 0.3 mol/ 
m3. In the surroundings in the vicinity of the GelMA 
hydrogel boundary, the spatial distribution of BMP-2 
for the lowest density model (2.5% w/v) shown in 
Figure 5a was distinct from that in the other higher 
density models shown in Figure 5c,e. More BMP-2 
diffuse to the region lacking BMP-2 in the low den-
sity model than in the other higher density models. 
Furthermore, owing to the possible diffusion effects 
from the neighboring GelMA hydrogel micropatterns 
on both sides, fluxes through either side boundary 
were not observed. The distribution showed a con-
vex-roof shape due to an upward movement along the 
side boundary. At 2,880 min (2 days), the BMP-2 dis-
tribution appeared to be apparently flat in the surr-
oundings near the GelMA hydrogel pattern for the 
lowest density model. The highest density model (10% 
w/v, shown in Figure 5e) still maintained a semicir-
cular shape of BMP-2 distribution, as high density of 
GelMA reduces diffusion of BMP-2 out of the pat-
terned GelMA hydrogel into the surroundings. The 
middle density model (5% w/v, Figure 5c) also showed 
a gradually flattening BMP-2 distribution in the sur-
rounding. On day 1, the concentrations at the center 
of each model decreased to half of the initial value. 
At 4,320 min (3 days), the highest density model fi-
nally showed a convex-roof shaped BMP-2 distribu-
tion curve in the surrounding, whereas almost flat BMP 




Figure 5. Computational simulation model based on the Millington and Quirk diffusivity model. (a−b) Lowest (2.5% w/v), (c−d) 
middle (5% w/v), and (e−f) highest (10% w/v) concentration of GelMA hydrogel. 
 
-2 distribution in the surroundings was observed for 
the other lower density models; this configuration is 
expected to be retained with gradual changes in con-
centration, to the end of boundary of the analysis 
domain over time. Interestingly, the concentrations of 
the highest density model were almost 2-fold higher 
than those of the lowest density model for 1, 2, and 3 
days. As the BMP-2 release from the GelMA mod-
eled as a 2D semicircle, the concentration of the drug 
in the GelMA gradually decreased over time due to 
diffusion, and the decrease rates differed with the de-
nsities of the GelMA hydrogel. Eventually, the BMP- 
2 concentration in the GelMA hydrogel approached 
that of the surrounding from the initial value. Figure 
5b,d,f shows the spatiotemporal variations of BMP-2 
concentrations along a hypothetical cut line connect-
ing the centers of both the patterned GelMA hydrogel 
and the top boundary of the surrounding, as indicated 
in Figure 5a,c,e. The initial concentration distribution 
shows a vertical drop at 125 μm corresponding to the 
pattern radius, indicating that BMP-2 molecules were 
uniformly distributed over the patterned volume. The 
diffusion occurred gradually into the surrounding. In 
the early stages, the distribution showed a steep gra-
dient near the interface in both domains. As time pro-
gressed, the molecules permeated the surrounding and 
the gradient changed gradually. As expected, the high-
est concentration model (10% w/v) showed the slow-
est gradient variation in concentration than the other 
lower density (2.5 and 5% w/v) models. In addition, 
at the last stage, the concentration at the center for the 
highest density model was the highest, indicating that 
the extent of BMP-2 retention in the GelMA hydrogel 
was the strongest. To determine whether the GelMA 
hydrogel micropattern can improve the sustainability 
of the BMP-2 drug carrier and to predict the release 
profile of BMP-2 from the GelMA hydrogel, FITC- 
BSA, instead of BMP-2 (similar amounts), was loaded 
on the hydrogel. Using fluorescent microscopy, the 
amount of FITC-BSA (excitation: 485 nm/emission: 
535 nm) released from the micropatterns to the outer 
phosphate buffered saline (PBS) due to difference in 
diffusion was measured over time and the emission 
amount was calculated for 6 days (Figure 6). Initially,  




Figure 6. Measurement of change in fluorescence intensity of FITC-BSA in patterned GelMA hydrogel for 6 days. (a−c) Lowest 
(2.5% w/v), (d−f) middle (5% w/v), (g−i) highest (10% w/v) concentration of GelMA hydrogel. 
 
each fixed FITC-BSA intensity was normalized to 
100. As shown in Figure 6a,d, and g on day 1, the low 
concentration case showed a rapid decrease of app-
roximately 75% fluorescence intensity (25.1 a. u.) due 
to the convulsive diffusion at the initial stage, and 
kept the decreased intensity for 6 days (22.0 a. u. on 
day 3 and 21.7 a. u. on day 6). Even at the medium and 
high concentrations, the rapid decreases of about 65 % 
(35. 2 a. u.) and 52 % (49.1 a. u.), respectively, were ob-
served only on the first day. On the 3rd day, the re-
duction rates of only 4 % (34.3 a. u.) and 6 % (45.2 a. 
u.) were observed, comparable to the first day (Figure 
6b,e, and h), and only the smallest reduction rates of 
5 % (33.7 a. u.) and 7 % (44.1 a. u.) were recorded on 
the last 6th day, respectively (Figure 6c,f, and i). It has 
been known that when the hydrogel is cross-linked, 
the swelling of the hydrogel is maximized for 24 
hours. As the concentration of the hydrogel decreases, 
the swelling degree increases and the density dec-
reases, whereas the swelling degree decreases and the 
density increases when the concentration increases41. 
Thus, the swelling of the GelMA hydrogel by cross- 
linking results in the volume changes of the patterns 
and redistribution of density within the patterns. Un-
der the same diffusion condition, the diffusive trans-
fer of FITC-BSA at the low concentration of GelMA 
is rapidly and easily made toward PBS solution. At 
the medium and high concentrations, the initial diffu-
sion rates are shown to be lowered by about 10 % and 
23 %, respectively, due to the relatively high density 
of the patterns. Although the experiments lasted for 6 
days, the results were consistent with those of the 
typical and ideal drug release profiles, which shows 
burst release in low density carriers and sustained re-
lease in high density carriers42-45. These results are si-
milar to those obtained using computational simula-
tions where BMP-2 is encapsulated in different con-
centrations of the GelMA hydrogel, indicating that  




Figure 7. Normalized release profiles of the FITC-BSA from the lowest, middle, and highest GelMA hydrogel. (a) Computational 
simulation for 3 days and (b) FITC-BSA loaded GelMA hydrogel micropattern after 6 days. 
 
BMP-2 can be released at different rates via localized 
and controlled release within the GelMA hydrogel 
micropatterns. Finally, we compared the experimen-
tal results with those of the simulation study. Altho-
ugh the simulation study lasted for only 3 days (Fig-
ure 7a) and the experiments were conducted for 6 
days (Figure 7b), the results of the simulation study 
and those obtained from the first 3 days of the expe-
riments were significantly similar. This indicated that 
the experiments were performed under optimal con-
ditions for reliable immobilization and release of 
BMP-2 from the patterned GelMA hydrogel. Based 
on the FITC-BSA release profiles in terms of the 
GelMA concentrations resulted from both simulation 
and experiments, the local release of BMP-2 would 
be expected to be controllable for more conditions. 
 
Osteogenic Differentiation of MG-63 Cells after 
BMP-2 Release 
To investigate the relationship between osteogenic 
differentiation and BMP-2 release, MG-63 cells were 
cultured in the absence or presence of BMP-2 on 2.5% 
(w/v) GelMA hydrogel micropattern and analyzed 
using actin filament staining and Alizarin Red S 
(ARS) staining (Figure 8). Although the SNM used 
as a substrate has an extracellular matrix-like surface 
structure, which can provide a good environment for 
cell attachment and proliferation44,46,47, MG-63 cells 
were observed to adhere primarily around the GelMA 
pattern. In particular, when BMP-2 was immobilized, 
the cells were observed to grow mainly when they 
were attached to the pattern and were in the vicinity 
of the pattern. When the cytoskeleton of the cells was 
observed using actin filament staining, we observed 
that a relatively rich and dense actin network was 
formed between MG-63 cells in the presence of 
BMP-2. In addition, in the absence of BMP-2 in the 
GelMA pattern, the cells tended to be located around 
the pattern in random direction (Figure 8a−c); how-
ever, in the case of BMP-2 immobilization, the cells 
were oriented toward the central axis of each pattern 
(Figure 8d−f). In terms of osteogenic differentiation, 
ARS staining was used to colorimetrically distinguish 
the extent of calcium deposition as a result of osteo-
blastic differentiation. Generally, the amount of cal-
cium in the medium increases when MG-63 cells in-
duce bone differentiation, and the calcium ion forms 
a strong covalent bond with oxygen or hydroxyl 
group in ARS, resulting in an orange-red precipitate 
48. Six days after seeding the MG-63 cells, calcium 
deposited nodules were observed under both condi-
tions. However, as shown in Figure 9, the calcium 
deposits formed by MG-63 cells on the surface of 
GelMA were significantly higher in the presence of 
BMP-2 (Figure 9c,d) than in the control group (Fig-
ure 9a,b). For quantitative analysis, the area of cal-
cium deposition was calculated using the ImageJ 
software. In the BMP-2 group, the average deposition 
area was approximately 32 mm2, whereas it was ap-
proximately 86 mm2 in the control group. These re-
sults show that BMP-2 was locally released from the 
GelMA micropattern, which significantly affected the 
osteogenic differentiation of MG-63 cells. The cal-
cium deposition correlated with the changes in the 
cytoskeleton after the release of BMP-2 (Figure 8). 
Despite these meaningful results, the clinical applica-
tion of the BMP-2 carrier is limited due to the short 
duration of 6 days and the in-vitro condition based on 
cell culture medium. Therefore, further studies such  




Figure 8. Actin filament staining of MG-63 cells after 6 days. (a−c) In the absence of BMP-2 and (d−f) in the presence of 2000 
ng/mL BMP-2 released from the 2.5% (w/v) GelMA hydrogel micropattern on SNM. 
 
 
Figure 9. Osteogenic differentiation of MG-63 cells with ARS staining after 6 days. (a−b) In the absence of BMP-2 and (c−d) in 
the presence of 2000 ng/mL BMP-2 released from the 2.5% (w/v) GelMA hydrogel micropattern on SNM. 
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as in vivo testing and alkaline phosphatase activity 
(ALP) assay are still needed. 
 
Conclusion 
In the clinical procedure of bone grafting on a defec-
tive site, a polymer-based barrier membrane is used 
to prevent invasion of connective tissue into the bone 
regeneration area49. However, although growth fac-
tors are used to promote bone formation, their use has 
been limited owing to problems such as burst release 
and action at the ectopic site depending on the growth 
factor carrier50. By optimizing the concentrations of 
BMP-2 and GelMA hydrogels for immobilization and 
micropatterning, respectively, we demonstrate that 
BMP-2 is easily immobilized into micropatterned 
GelMA hydrogels and that the local release of BMP 
-2 is effectively controlled. The GelMA hydrogels 
provide an environment in which BMP-2 can be ho-
mogeneously laden, while the SNM supported trans-
mission of UV light, allowing the GelMA hydrogels 
containing BMP-2 to crosslink rapidly on the SNM 
surface. The behavior of MG-63 cells in bone differ-
entiation medium depended on the distribution of 
BMP-2, indicating that bone differentiation of MG- 
63 cells can be manipulated by controlling the immo-
bilized BMP-2 in the GelMA hydrogel micropattern. 
The proposed method can be applied to various clini-
cal treatments requiring controlled delivery of growth 
factors and cells, such as in bone regeneration, where 
the pattern size and concentration of BMP-2 can be 
changed depending on the size of the bone defect or 
the type of bone graft. 
 
Materials and Methods 
PDMS Concave Micromold for Micropatterning 
A polymeric concave micromold was used to facili-
tate BMP-2 immobilization into the GelMA hydrogel. 
For fabricating a PDMS (Dow Corning, MI, USA)- 
based concave micromold using a replication process, 
a well-defined photo-lithography method was used 
with the photosensitive epoxy resin (SU-8, Micro-
Chem, MA, USA)51,52. A hemispheric SU-8 poly-
meric convex master mold, which commonly uses an 
epoxy-based negative photoresist according to a pub-
lished protocol, was used51. Briefly, to make a master 
mold, a perforated SU-8 shadow mask layer with ar-
rayed holes (diameter: 250 μm) was designed. Then, 
the perforated SU-8 shadow layer was exposed to UV 
light for SU-8 polymerization with the designed pho-
tomask film. Following curing and development of 
the SU-8 photoresist, the Kapton film and SU-8 were 
separated from a Si-wafer, and the Kapton film was 
carefully removed from the SU-8 photoresist layer, 
which was used as a shadow mask. The radius of each 
pattern was 250 μm, and they appeared at intervals of 
250 μm. Finally, to replicate the concave micromold, 
the PDMS solution was mixed at a 10 (base):1.2 
(curing agent) weight ratio. The mixed solution was 
stirred for 10 min with a stirring stick and vacuumed 
to eliminate residual bubbles. The PDMS solution 
was poured into the prepared SU-8 master mold, and 
heated to 80 °C for 30 min. Then, after annealing to 
the hotplate, the replicated PDMS concave micro-
mold was separated from the SU-8 master mold. 
 
GelMA Hydrogel Micropatterns on SNM 
Localized GelMA hydrogel patterning was performed 
via in situ photo-polymerization using prepared the 
PDMS concave micromold and electrospun SNM. 
After autoclaving (for sterilization), the surfaces of 
the PDMS concave micromold and SNM were treat-
ed with 60 W oxygen plasma (Cute, Femto-Science, 
Inc.) for easy filling and adsorption of GelMA solu-
tion (Figure 1b,c)53. Then, 1 mL of 2.5, 5, and 10% 
(w/v) GelMA solution was filled onto the PDMS 
mold and the excess solution was removed using a 
rubber scraper. Next, SNM (15 × 15 mm) was used to 
cover the PDMS concave micromold. For pho-
to-crosslinking the SNM, the covered SNM surface 
was exposed to UV light (Omnicure S2000, Mari-
times, Canada) (wavelength: 360 nm, intensity: 
10,000 mW/cm2) at distance of 8 cm for 30 s54. The 
photo-crosslinked GelMA hydrogel micropatterns 
were obtained by peeling the SNM from the PDMS 
mold as shown in Figure 2b,c. As shown in Figure 
3b,c, to observe and visualize the photo-cross-linked 
GelMA hydrogel micropatterns on SNM, 2.5% (w/v) 
GelMA solution was mixed with trypan blue (Sig-
ma-Aldrich, St, Louis, MO, USA) and FITC-BSA 
(70 kDa) (Sigma-Aldrich) solution. In addition, to 
determine the BMP-2 immobilization ability of vari-
ous materials, 5 μm fluorescent silica beads were 
mixed and cross-linked with the GelMA hydrogel 
and scanned using confocal microscopy. The images 
were analyzed to determine whether the beads were 
homogeneously dispersed in the hemispherical mi-
cropatterned GelMA hydrogel (Figure 3d−f). 
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Mechanical Properties and Adhesion Stability 
A digital force gauge meter (FGV-50XY, Shimpo Co. 
Japan) was used for the measurement of the com-
pressive strength of the micropatterned GelMA hy-
drogel on the SNM. Deformation was observed by 
pressing the micropatterned GelMA hydrogel with 
the tip of an ink pen (Movie S1, Supporting Infor-
mation). Simultaneously, for evaluating the adhesion 
between the GelMA hydrogel micropatterns and the 
SNM surface, the GelMA hydrogel micropatterned 
SNM was stretched several times in the horizontal, 
vertical, and diagonal directions and the separation of 
the GelMA micropattern from the SNM was obser-
ved (Movie S2, Supporting Information). In addition, 
the tensile strength was examined using a micro-uni-
versal testing machine (UTM) (LR10K-plus, Lloyd 
Instruments Ltd., UK) under a crosshead speed of 50 
mm/min at room temperature. The specimens were pre-
pared as rectangles (10 × 50 mm) containing GelMA 
hydrogel micropatterns. During the testing, a mois-
turizing mist was intermittently sprayed onto the 
specimens to prevent dehydration of the GelMA hy-
drogel (Figure S5, Supporting Information). 
 
Estimation of the Release Profile of BMP-2 from 
the Micropatterned GelMA Hydrogel 
To assess the fundamental release profile determining 
the concentration of the GelMA hydrogel, the Mil-
lington and Quirk model for drug transport was theo-
retically studied using a computational porous mate-
rial with effective transport properties. The surround-
ings were modeled in the shape of a rectangle of 500 
μm width and 1000 μm height, while the actual depth 
of the culture medium in the experiments was several 
orders of magnitude higher than the height of the sur-
roundings of the simulation. Therefore, the top boun-
dary condition of the surroundings was defined to be 
of the external convection type of flux with a mass 
transfer coefficient. The boundary condition of both 
sides was set to no flux of drugs through the bounda-
ry via diffusion from the neighboring surroundings. 
The bottom surface of the surrounding was also un-
der no flux condition. The half-circular boundary of 
the surroundings adjacent to the GelMA top surface 
was assumed to have the same concentration as that 
of the surface. A simple 2D model analyzed using the 
COMSOL® Multiphysics software, a commercial fi-
nite element method (FEM)-based simulation tool 
(version 5.4, module Chemical Species Transport and 
Transport of Diluted Species in Porous Media, 
COMSOL Inc., Burlington, MA, USA), was used for 
numerical analysis to emulate the diffusive transfer of 
BMP-2 in GelMA hydrogel under three different con-
centrations. As the actual size of the pores in hydro-
gel materials is typically several orders of magnitude 
smaller than the model domain to be analyzed and is 
difficult to be described in detail, a simple 2D porous 
model with effective porosity was defined using the 
simulation. The equation for the time-dependent model 
is based on the Millington and Quirk diffusivity mo-









                              (2) 
 
where c denotes the concentration (% w/v), DD the 
dispersion coefficient (m2/s), De the diffusion coeffi-
cient (m2/s), ∈ the porosity,  	the effective diffu-
sivity which is equal to ∈
 ⁄ , and DF the fluid 
diffusion coefficient (m2/s). This computational sim-
ulation solves only diffusion and dispersion problem 
by mass transfer in porous media due to concentra-
tion gradient, and no forced convection mechanism 
was considered in the GelMA hydrogel domain. The 
initial condition of drug concentration was set to 

 = 0. As shown in Figure 4a−c, both GelMA 
and the surroundings were discretized in 2D-triangular 
meshes using predefined extra fine element size with 
maximum diameter of 20 μm. For high accuracy and 
rapid convergence of the results, the half-circular 
boundary between patterned GelMA hydrogel and the 
surroundings were also discretized using the boun-
dary layer properties, with 8 layers for both sides and 
boundary layer stretching factor of 1.2. The maxi-
mum element size was 5 μm. The structure of GelMA 
hydrogel micropattern model for the simulation is 
assumed to be a half circle with a radius of 125 μm, 
and the space between the neighboring structures is 
250 μm, which is based on the actual patterned 
GelMA hydrogel dimensions. Instead of simulating 
the full-scale actual micropattern (8 by 8), only one 
structure and the surroundings in the vicinity were 
analyzed. The initial condition of drug concentration 
in the GelMA hydrogel domain is defined as a con-
stant, 	 = 	  . The boundary condition at the 
bottom surface of the GelMA hydrogel was set to no 
flux of drug through the boundary, while the external 
convection flux was considered the boundary condi-
tion at the top surface, which was not due to forced 
convective flux, but due to diffusion arising from the 
concentration differences between the micropattern 
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and the surroundings as described in the following 
equation. 
 
−D + D∇c ∙ n = kc − c	
            (3) 
 
Where 	
  denotes the normal vector, km is the 
mass transfer coefficient (m/s) in GelMA, and csur 
denotes the concentration [% (m/v)] in the surround-
ing domain. In addition, to predict the release profile 
of BMP-2 (30 kDa) (which will be immobilized later), 
the release profile of FITC-BSA (70 kDa) from the 
micropatterned GelMA hydrogel was assessed using 
an inverted fluorescence microscope (Axiovert 200M, 
Carl Zeiss, Darmstadt, Germany). The samples were 
prepared with the lowest, middle, and highest con-
centrations of GelMA solution (2.5, 5, and 10% w/v) 
(Figure 5). To emulate the in vivo condition, 3 mL 
PBS solution was changed each time after sampling 
over 6 days. The same spot of each sample was mon-
itored daily to observe the changes in the fluores-
cence intensity of FITC-BSA measured over time. 
 
Evaluation of Osteogenic Differentiation and 
Morphology 
To evaluate the effect of osteogenic differentiation, 
including morphology, on the localized and controlled 
release of BMP-2, human osteoblast-like MG-63 cells 
(American Type Culture Collection, Rockville, MD, 
USA) were cultured onto the GelMA hydrogel micro-
patterned SNM for 6 days. In particular, before the 
pattering process, the SNM was fixed onto the bottom 
of the cell culture dish using half-cured PDMS solu-
tion and dried for preventing the floating of SNM in 
the culture media. The cell density was 1 × 106 cells/ 
mL, and 100 μL cells were seeded onto the BMP-2 
(2000 ng/mL)-immobilized GelMA hydrogel micro-
patterned SNM. In addition, MG-63 cells were sim-
ultaneously cultured on SNM without BMP-2 as the 
control group. The cells were cultured in cell media 
[10% (w/w) Dulbecco’s modified Eagle’s medium 
(DMEM)] (Gibco, CA, USA) supplemented with 1% 
(w/w) fetal bovine serum (FBS) (Gibco) and 1% 
(w/w) penicillin/streptomycin (Gibco) in a humidi-
fied atmosphere containing 5% CO2 at 37 °C. After 6 
days, the actin filaments were stained with Alexa 
Fluor 568 phalloidin fluorescent dye (Invitrogen, Eu-
gene, OR, USA) to determine the cytoskeletal organ-
ization in MG-63 cells. Image-iTTM FX signal en-
hancer was used to enhance the signal-to-noise ratio 
of fluorescently labeled cells, and fluorescent images 
were acquired and processed using an Axiovert 200 
inverted microscope. Osteogenic differentiation was 
evaluated by staining the calcium deposits using the 
ARS staining kit (pH 4.1–4.3; Sigma-Aldrich)55. First, 
the culture medium was removed, and the cells were 
gently washed thrice with PBS. Next, the cells were 
fixed with 4% (w/v) formaldehyde for 15 min at room 
temperature. Then, the cells were washed with dis-
tilled water, followed by the addition of 2% (w/v) 
solution of 60 mM ARS, the pH to 4.1−4.3 of which 
was adjusted using NH4OH and HCl solutions. After 
filtering the ARS solution with a 0.2 μm filter, 1 mL 
of the ARS solution was dropped onto the SNMs and 
incubated for 1 h at 4 °C. Then, the stained cells were 
photographed to analyze the calcium deposits in-
duced by released BMP-2. 
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